Author: Rostami Mansoor, Sahar; Ghasemiâ€Kasman, Maryam
Title: Impact of diseaseâ€modifying drugs on the severity of COVIDâ€19 infection in multiple sclerosis patients Cord-id: 7zbl391x Document date: 2020_10_30
ID: 7zbl391x
Snippet: Recent evidence suggested that neurological manifestations occur in patients with a severe form of coronavirus disease (COVIDâ€19). On the basis of this issue, neurologists are very concerned about patients with neurological disorders, especially multiple sclerosis (MS), as consumers of immunosuppressive or immuneâ€modulating drugs. Therefore, the administration of proper diseaseâ€modifying therapies (DMTs) in MS patients is critical during the pandemic status. On the one hand, both the autoi
Document: Recent evidence suggested that neurological manifestations occur in patients with a severe form of coronavirus disease (COVIDâ€19). On the basis of this issue, neurologists are very concerned about patients with neurological disorders, especially multiple sclerosis (MS), as consumers of immunosuppressive or immuneâ€modulating drugs. Therefore, the administration of proper diseaseâ€modifying therapies (DMTs) in MS patients is critical during the pandemic status. On the one hand, both the autoimmune diseases and immunosuppressive drugs increase the risk of infection due to impairment in the immune system, and on the other hand, postponing of MS treatment has serious consequences on the central nervous system. In the present study, we discussed recent literature about the effect of DMTs administration on the severity of COVIDâ€19 in the MS patients. Overall, it seems that DMTs do not provoke the COVIDâ€19 infection in the MS patients by declining immune responses and cytokine storm. However, as a precaution, the supervision of a neurologist is highly recommended.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lymphocyte depletion: 1
- adaptive innate and lung alveolar: 1, 2, 3
- adaptive innate and lymphocyte count: 1, 2
- adaptive innate and lymphocyte depletion: 1
- adaptive innate immunity and lung alveolar: 1
- adaptive innate immunity and lymphocyte count: 1
- lung alveolar and lymphocyte count: 1
Co phrase search for related documents, hyperlinks ordered by date